What is the appropriate management of a urinary tract infection in a patient with a double‑J ureteral stent?

Management of UTI in Patients with Double-J Ureteral Stents

Treat symptomatic UTIs in patients with double-J stents with targeted antimicrobial therapy based on urine culture and susceptibility testing for 7-14 days, but do NOT treat asymptomatic bacteriuria or use continuous antibiotic prophylaxis during stent indwelling time.

Key Management Principles

Distinguish Symptomatic UTI from Asymptomatic Bacteriuria

The most critical decision is determining whether the patient has a true infection requiring treatment:

Symptomatic UTI indicators:

• Fever, rigors, or systemic symptoms
• New or worsening flank pain beyond typical stent discomfort
• Altered mental status (especially in elderly)
• Signs of sepsis or hemodynamic instability

Do NOT treat if the patient only has:

• Positive urine culture without symptoms
• Typical stent-related lower urinary tract symptoms (frequency, urgency, dysuria) without fever
• Asymptomatic bacteriuria 1

This distinction is crucial because surveillance cultures and treating asymptomatic patients should be discouraged to avoid multidrug-resistant organisms 1.

Treatment of Confirmed Symptomatic UTI

For symptomatic UTI with double-J stent in place:

1. Obtain urine culture before starting antibiotics - essential for targeting therapy 1

2. Empiric therapy should cover expected uropathogens:

   • Common organisms: Pseudomonas, E. coli, Stenotrophomonas, Klebsiella, Enterococcus spp.
   • Up to 50% may be polymicrobial 1
   • Consider ceftriaxone or ampicillin/sulbactam for high-risk patients (immunocompromised, recurrent UTIs, uncontrolled diabetes, history of infected stones) 1
   • For stable patients: ciprofloxacin or trimethoprim-sulfamethoxazole 1

3. Treatment duration: 7-14 days 2, 3

   • 7 days may be sufficient for patients improving on effective therapy 3
   • Consider 10-14 days if acute bacterial prostatitis suspected in men 3
   • Adjust based on culture results and clinical response 2

4. Assess need for stent removal or exchange:

   • The single most important intervention is removing the stent if clinically feasible 1
   • Length of time the device remains in place is the main risk factor for infection 1
   • If stent must remain, consider exchange if heavily colonized or obstructed 1

What NOT to Do

Avoid these common pitfalls:

• No continuous antibiotic prophylaxis during stent indwelling time - multiple high-quality studies show no benefit 4, 5, 6

  • Study of 178 patients: continuous ciprofloxacin showed no reduction in UTI (3.4% vs 4.4%, p=0.722) or stent symptoms 6
  • Study of 90 patients: 7-day oral antibiotics at discharge showed no difference in UTI rates (p=0.95) 4
  • Prophylaxis only increases antibiotic resistance and side effects without clinical benefit 4, 5, 6

• No routine surveillance cultures in asymptomatic patients 1

• No routine stent exchanges solely for infection prevention 7

• Avoid concomitant Foley catheters with ureteral stents when feasible 1

Special Considerations for Severe Infection

If patient presents with sepsis or pyonephrosis:

• This is a urologic emergency requiring immediate drainage 8
• Start broad-spectrum IV antibiotics immediately (cover Gram-negatives and Pseudomonas)
• Remove or exchange the stent urgently - antibiotics alone are insufficient 8
• Consider percutaneous nephrostomy if stent exchange not feasible 8
• Expect clinical response with defervescence by 72 hours; if not, consider urologic evaluation for obstruction or abscess 2

Prevention Strategy

The best approach to prevent stent-related infections:

1. Periodically reassess need for the stent - remove as soon as clinically possible 1
2. Routine replacement every 3 months (or more frequently if high risk for obstruction) to prevent biofilm formation, encrustation, and subsequent infection 1
3. Preprocedural prophylaxis at time of stent placement/exchange with agents covering uropathogens (ceftriaxone or ampicillin/sulbactam preferred over cefazolin) 1

Evidence Quality Note

The 2023 CA Cancer Journal guidelines 1 provide the most recent and comprehensive guidance on device-related urinary infections, specifically addressing double-J stents. Multiple recent randomized trials 4, 5, 6 consistently demonstrate no benefit of continuous antibiotic prophylaxis, contradicting older practices. The 2019 IDSA guidelines 9 and 2024 EAU guidelines 10 support not treating asymptomatic bacteriuria in catheterized patients, a principle that extends to stented patients.